Objective: The study objective was to evaluate trends in the use of surgical therapy for patients with early-stage (IA-IIA) non-small cell lung cancer when stereotactic ablative radiotherapy was introduced in the United States.
See Editorial Commentary page 1247.
Lung cancer is the leading cause of cancer-related death in the United States with 224,390 new cases and 158,080 deaths estimated in 2016. 1 For patients with early-stage (stage IA-IIA) non-small cell lung cancer (NSCLC), surgical resection provides the best chance for cure. 2 However, because of the etiology of lung cancer, many patients have age-and smoking-related comorbidities, contributing to increased surgical risk. Although some of these patients are clearly not surgical candidates because of medical comorbidity, there remains a large cohort for whom the decision to operate is not clear-cut. Because of the aging US population and current screening guidelines supporting the use of computed tomography in groups at high risk for lung cancer, the number of potentially resectable lung cancers in these moderate-risk patients is expected to increase.
In the past decade, stereotactic ablative radiotherapy (SABR) has emerged as an alternate to surgical therapy for high medical risk patients with localized disease. SABR delivers focused external beam radiation at ablative doses in 1 to 5 fractions. 3 Treatment is completed in an outpatient setting over approximately 2 weeks. The benefits over traditional radiation therapy include a focused treatment target, minimizing radiation-induced damage to adjacent parenchyma, and a shorter treatment schedule thereby reducing inconvenience to the patient. 4 Survey data suggest approximately half of radiation oncologists were routinely using SABR for patients with NSCLC by 2008. 5 Multiple analyses, including meta-analyses and Markov decision models, have suggested outcomes comparable to resection in medically inoperable patient populations with regard to locoregional control, disease-free survival, and overall survival. 4, [6] [7] [8] [9] [10] [11] However, randomized clinical trials evaluating SABR for potentially operable patients have failed to accrue patients and have closed early (STARS trial [NCT00840749], ROSEL trial [NCT00687986] , and ACOSOG Z4099 trial [NCT01336894]). [12] [13] [14] When treatment technology evolves more rapidly than randomized clinical trials can be completed, treatment trends in the community do not always reflect the available level 1 data. 15 Despite current evidence, little is known about the effect that the introduction of SABR has had on the use of surgery for early-stage lung cancer. By using the National Cancer Data Base (NCDB), we sought to determine the following for patients treated in the United States: (1) the trend in the rate of surgical therapy, as well as alternate treatment modalities, for patients with early-stage (IA-IIA) NSCLC; (2) the reported reasons for not receiving surgery, as documented in the NCDB; and (3) the identification of factors associated with receipt of surgery compared with radiation.
MATERIALS AND METHODS Data Source
Data were obtained from the NCDB, a joint program of the American College of Surgeons and American Cancer Society. The largest cancer registry in the world, the NCDB is estimated to capture approximately 70% of all new cancer diagnoses in the United States and Puerto Rico, including 82% of lung cancer diagnoses. 16 Data are collected by Certified Tumor Registrars who undergo extensive training and are audited to ensure accuracy of the database. Hospital and patient identity are protected and not included in the Participant Use File. Data released in the Participant Use File are in compliance with the privacy requirements of the Health Information Portability and Accountability Act. The Institutional Review Board at Northwestern University determined this study was exempt because it uses publicly available de-identified data.
Patient Selection
The 2014 NCBD Participant Use File was queried to identify patients diagnosed with NSCLC from January 1, 2004, to December 31, 2013. We included all patients with a clinical or pathologic stage of IA to IIA NSCLC, as determined by the American Joint Committee on Cancer 6th or 7th Edition Cancer Staging Manual, which do not differ with respect to staging for our patient population of focus. 17 Patients with clinical N1 disease were excluded because they would not be candidates for SABR. If there were discrepancies between clinical and pathologic stage determination, we preferentially used clinical stage to reflect the information available at the time a treatment decision was made. We excluded patients with missing treatment data (n ¼ 29,277, 2.5%). In addition, patients with previous cancers, recurrent cancer, or possible metastatic disease from an extrathoracic primary tumor were excluded from the analysis because these groups were thought to represent a biologically distinct disease process (n ¼ 92,450; 7.9%). Trends in care were analyzed for the entire patient cohort. Regression modeling focused on the most recent 3 years to most closely reflect decision making in current use patterns.
Treatment Modalities
We grouped eligible patients by the primary treatment modality used for their primary tumor. Surgical patients include those who underwent sublobar resection (including segmentectomy and wedge resection), lobar or bilobar resection, or pneumonectomy. We did not differentiate between the various radiation protocols because the ideal protocol for SABR is still being defined, protocols varied when this modality was introduced, and, as a result, abstraction may have been inconsistent. 9 Thus, patients coded as receiving radiation therapy included both SABR and any other form of radiation therapy. It should be emphasized that throughout this article ''radiation'' refers to all forms of radiation therapy where ''SABR'' will refer specifically to stereotactic ablative radiotherapy. The ''Other'' category includes patients who were documented to have received treatment with curative intent, for example, radiofrequency ablation or doublet chemotherapy. The patients included in the ''No curative treatment'' group included patients who received single-agent chemotherapy regimens, hormonal therapy, or immunotherapy, as well as patients undergoing active surveillance.
Statistical Analysis
In the unadjusted analysis, we performed a For the nonsurgical group, we generated descriptive statistics for the alternate treatment modalities during the study time period, as well as the reason recorded for not receiving surgical therapy. We then estimated a multivariable logistic regression model with receipt of surgery (vs radiation) as our outcome variable to identify factors associated with the decision between ultimate receipt of surgery and radiation. We included patients diagnosed between 2011 and 2013 to reflect the most current decision-making practices available. Patient clustering by treating facility was accounted for in our model with the robust covariance matrix estimator (unidimensional clustering) because of the large number of treating facilities (n ¼ 1235).
Covariate Selection
We chose covariates a priori on the basis of the identification in the literature of factors associated with disparities in surgical care and forced these into our model. 2, [18] [19] [20] [21] [22] These factors included year (modeled as a categoric variable), tumor characteristics (histology and stage), patient-level factors (age, race/ethnicity, sex, median income, median education level, insurance status, and modified Charlson-Deyo comorbidity score 23 ), and hospital-level factors (a combined variable that takes into account both the hospital volume and the academic status of the hospital). Because histology is known to affect survival and therefore may affect the decision to operate, we included histology as a categoric variable with 3 groups: adenocarcinoma, squamous cell carcinoma, or other non-small cell carcinoma. All patients in the NCDB have documented histology; thus, patients who are treated without a histologic diagnosis documentation were not included in this analysis. We grouped patients according to the American Joint Committee on Cancer clinical stage recorded in the NCDB. Age was included as a continuous variable. Race and ethnicity were grouped into 4 categories as defined by the Commission on Cancer (CoC): nonHispanic white, non-Hispanic African-American, Hispanic, and other. Race and ethnicity were abstracted from patient charts by NCDB abstractors; because each hospital may vary with regard to how patient race and ethnicity were entered into charts, it was not possible to determine whether these data were self-reported or not. Patients were grouped into quartiles for income and education derived from census data for their ZIP code, as defined by the CoC. Insurance status was dichotomized into 2 groups presumed to represent lower and higher socioeconomic status: Medicaid and uninsured versus all others. 24 A modified Charlson-Deyo comorbidity score was included as a categoric variable as defined by the CoC: zero, 1, and 2 or more. Facility characteristics were accounted for in the model with a variable representing volume and academic status. For this variable, ''high volume'' refers to hospitals in the top quartile for number of unique patients treated for lung cancer, averaged over the study time period. Academic hospitals were defined by the CoC as having 500 or more newly diagnosed cancer types per year and offering graduate medical education programs in greater than 4 disciplines. We assessed for and did not find a significant interaction between insurance status and income level, between facility and income level, or between facility and insurance status. Therefore, no interaction term was included in our final model. Analyses were performed using STATA v14 (StataCorp LP, College Station, Tex) and SAS v9.4 (SAS Institute Inc, Cary, NC) statistical software.
RESULTS

Baseline Patient Data
We analyzed 200,404 eligible patients ( Figure 1 ). Patients undergoing surgery were younger and white, and were treated at high-volume academic centers (Table 1) . Of note, patients who received radiation had fewer comorbid conditions documented. (Figure 2 ). The proportion of early-stage lung cancers compared with the overall number of lung cancer diagnoses is shown in Figure E1 .
Alternate Treatment Before and After Stereotactic Ablative Radiotherapy Availability
Of nonsurgical patients (n ¼ 40,461), the majority were treated with radiation (n ¼ 32,244; 79.7%), and 13.4% of patients (n ¼ 5431) received no curative treatment. A minority (n ¼ 2786; 6.9%) of nonsurgical patients were treated with some other modality, including radiofrequency ablation, chemotherapy, and experimental methods.
Comparing the first 2 years and last 2 years of the study time period (Table 2) , the proportion of patients receiving radiation therapy increased by 5.6% (95% confidence interval [CI], 5.1-6.1). Comparing the same 2 groups of patients, the proportion of patients receiving surgical therapy decreased by 8.8% (95% CI, 8.3-9.4), and the proportion of patients receiving no curative treatment increased by 3.7% (95% CI, 3.5-3.9) (absolute percentages).
Reason for Not Receiving Surgery
The most common reason recorded for not undergoing surgery was that an alternate treatment was recommended as first-line therapy (n ¼ 27,986; 69.2% of patients in the nonsurgical cohort). Approximately 20.5% (n ¼ 8283) of patients were noted to not be surgical candidates because of patient risk factors (eg, medical comorbidities or advanced age). We found 4.6% (n ¼ 1849) of patients did not receive recommended surgery because the patient or patient's family refused. In 0.7% of patients (n ¼ 283), surgery was recommended but not performed for unknown reasons, and in 1.9% of patients (n ¼ 764), it was unknown if surgery was recommended.
Comparing the first 2 years and last 2 years of the study time period, the proportion of patients and families who refuse a recommended operation increased from 3.7% to 5.3% (P < .0001). All other reasons for refusal did not change over the study time period.
Adjusted Analysis
In our multivariable logistic regression model (Table 3 ), earlier year of diagnosis was significantly associated with receiving surgical therapy compared with radiation. Patients were more likely to undergo surgery if they were younger and white, lived in higher income areas, or had
The Journal of Thoracic and Cardiovascular Surgery c Volume 156, Number 3earlier-stage disease or adenocarcinoma histology. Conversely, uninsured patients or those with Medicaid as their primary payor were less likely to have received surgery.
DISCUSSION
In this time-trend analysis of NCDB data on patients diagnosed with potentially resectable stage IA to IIA NSCLC from 2004 to 2013, we aimed to determine the trend in therapy and factors associated with receipt of surgery in the modern era. We found that there has been an increase in both the use of radiation and the proportion of untreated patients. Concomitantly, we found a decrease in the rates of surgical resection over this same period.
The reason for the decreased use of surgery for earlystage NSCLC is unclear but may be related to changes in health policy, changes in patient preferences, or changes in referral patterns. The National Lung Screening Trial resulted in an update to the United States Preventative Services Task Force recommendation for lung cancer screening in 2013. 25 This may have resulted in increased detection of early-stage cancer in medically inoperable patients and therefore a decrease in the use of surgery. However, these recommendations were published in 2013 and are still not closely followed; recent data suggest less than 5% of eligible patients were screened according to guidelines in 2015. 24 Moreover, recommendations state that patients should be candidates for curative lung surgery to be eligible for screening. Therefore, we think it is unlikely that this health policy change explains our findings in their entirety.
There may be other factors influencing the treatment trends we report, including physician factors 26 and patient and family care preferences. As a clinically abstracted dataset collected secondarily from medical records, the NCDB is limited to information documented in patients' medical charts. However, from the data available, we were able to show that most patients who did not receive surgery underwent radiation therapy, whereas a minority received no curative therapy. This is consistent with the corresponding finding that the majority of patients who did not receive surgery were recorded as having an alternate therapy recommended as first line by one of their physicians. However, a subset of patients or families refused surgery even though it was recommended as primary treatment. Although there will likely always be a subset of patients for whom surgery does not align with their values, it is imperative that physicians ensure adequate education regarding the risks and benefits of all available treatment options.
There is limited research regarding patient preferences in lung cancer care worldwide, and specifically there are little published data examining treatment in the US population. A prospective cohort study of US patients with NSCLC used a regression analysis of survey data to identify factors associated with the decision to undergo surgery: perception of communication and prognosis, older age, multiple comorbidities, and African-American race were associated with nonoperative treatment. 27 We were able to account for some of these factors in our analysis (age, comorbidity score, and race were available for all patients), but we did not have data regarding patient perceptions. A study of German patients with NSCLC suggested that patient preferences may be influenced by factors of interest to clinicians as well: progression-free survival and tumor-associated symptoms. 28 However, these results may not be generalizable to the US population. Although there are limited data on family preferences for lung cancer care, a study of patients with lung and colon cancer in the United States suggests that the majority of patients reported at least some involvement of family in decision-making. 29 Future survey-based or qualitative research in the United States is needed to define patient and family preferences for lung cancer care.
For clinical situations in which treatment technology is evolving faster than randomized clinical trials can be completed, treatment trends in the community do not always reflect the available level 1 data. 15 Two European time-trend analyses of treatment trends in older patients with stage I NSCLC showed an increase in the rates of radiation treatment with a concomitant decrease in the proportion of untreated patients, but no change in the proportion of patients treated with surgery. 30, 31 These data suggest that SABR was being used appropriately for highrisk patients who otherwise would not be treated. In contrast, our analysis of patients of all ages with stage I to IIA NSCLC indicates that the increase in radiation was accompanied by a potentially inappropriate decrease in the proportion of patients treated with surgery. Qualitative or survey-based studies to better understand the reasons for this decrease in the rate of surgical therapy are needed.
Although current treatment guidelines do not recommend SABR as first-line treatment for moderate-risk patients with NSCLC, multiple observational studies have suggested therapeutic equipoise exists between SABR and surgery. A systematic review of studies published between 2006 and 2013 showed an equivalent 2-year overall survival between SABR and surgery. 9 Likewise, a meta-analysis of articles published between 2000 and 2012 indicated no significant difference in overall survival between the 2 treatment strategies. The analysis was limited by the lack of direct comparison between groups, because the majority of articles included were reports on the survival of a cohort of patients treated only with surgery or a cohort of patients treated only with SABR. A propensity score-matched analysis of 128 patients with stage I or stage II NSCLC reported similar overall survival and 3-year freedom from progression between SABR and surgery. 11 Moreover, in this dataset, the authors found superior locoregional control in patients treated with SABR. However, a more recent propensity score-matched analysis of 102 patients with stage I NSCLC reported significantly better overall survival and disease-free survival in their surgical cohort, 6 and a recent NCDB analysis of 15,343 healthy patients with stage I NSCLC reported significantly better overall survival in the surgical cohort. 32 In an attempt to prospectively determine the comparative effectiveness of surgery versus SABR for patients with early-stage NSCLC, 3 randomized controlled trials were initiated; however, all 3 trials were closed early because of poor accrual. A recent pooled analysis of data from 2 of these trials, STARS and ROSEL, concluded that the data indicated therapeutic equipoise for patients with T1-T2a primary and node-negative disease, and the authors reported better overall survival in the SABR cohort. 4 This study was limited by a small sample size, especially in long-term follow-up (only 27 patients were still at risk at 3 years). Although these trials were limited by poor accrual, they did add important insights for SABR protocols in future trials. One trial, SABRTooth (ISRCTN13029788), completed enrollment from centers in the United Kingdom in early 2017. 33 A Veterans' Affairs-based trial, VALOR (NCT02984761), is active but not yet enrolling. 34 In both of these studies, screening and enrollment will be performed by a pulmonologist and research nurse to reduce the bias introduced by thoracic surgeons and radiation oncologists. A US-based study, STABLE-MATES (NCT02468024), is enrolling candidates at high risk for surgery. The study is projected to complete data collection for the primary end point of 3-year overall survival in 2018. 35 It is our opinion that participation in these trials should be encouraged when possible.
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Study Limitations
There are limitations to our study. First, data extracted from any database are subject to coding error. However, the NCDB data are collected by trained and audited abstractors, improving reliability. In addition, the data definitions are standardized. Thus, the effect of these differences is likely minimal. Second, all patients who had stage IA to IIA, and thus eligible for surgery based on stage, were evaluated. Because of the limitations of the NCDB data fields, we are unable to make further judgments on a patient's eligibility for surgical intervention. For example, no data for performance status or pulmonary function tests were available. Although the overall Charlson-Deyo score was available, more granular details about individual comorbidities were lacking. The surprising finding that people with 1 comorbidity were more likely to undergo surgery than patients with zero comorbidities highlights the potential problem with relying on a comorbidity score to accurately reflect the medical operability of a patient. Third, these data may be limited by selection bias because we analyzed only CoC-accredited hospitals that report to the NCDB. However, this file contains more than 80% of all lung cancer cases from a variety of hospitals that vary in type and size. 16 Last, because CoC accreditation may change from year to year for individual facilities, the characteristics of the facilities represented in the database in 2004 may be substantially different from those in 2013. However, because of the large number and range of facilities, it is unlikely that treatment bias on the individual facility level would substantially affect our findings.
CONCLUSIONS
Our data demonstrate an overall decrease in the use of surgical therapy for lung cancer in early-stage disease. Because resection remains the standard of care for most patients with early-stage disease, these data indicate a potentially significant quality gap in the treatment of NSCLC. Further comparative effectiveness analyses are needed to compare both oncologic outcomes and patient-reported outcomes between surgical resection and SABR to define standards of care for all patient populations. The results of 3 large randomized trials comparing SABR and surgery for early-stage NSCLC are highly anticipated. In the meantime, qualitative or survey-based investigation of stakeholder perspectives may help to define the reasons for this quality gap in the treatment of patients with early-stage NSCLC.
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